Biocon Limited has announced the results of an ascending dose study with oral insulin drug (IN-105) at the European Association for the Study of Diabetes (EASD) meeting in Rome. The study involved dosing type-2 diabetes subjects with single doses of 0 mg (placebo), 10 mg, 15 mg, 20 mg and 30 mg tablets of IN-105 in 5 separate periods before a mixed 600 kcal breakfast. The outcome measurements were the safety and tolerability of IN-105, as well as the pharmacokinetics and pharmaco-dynamics of IN-105. The results showed that IN-105 was safe and well tolerated by patients.
The details can be read here.
No comments:
Post a Comment